{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:06:50Z","timestamp":1770991610505,"version":"3.50.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> To summarize the situation of antineoplastic agents-induced interstitial lung diseases (ILD), provide reference for strengthening clinical management of druginduced interstitial lung diseases (DILD).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We retrospectively investigated the medical records of 12 patients with antineoplastic agents-induced ILD in a hospital between January and December 2020. Data collected included patients\u2019 characteristic (gender, age, ECOG PS score, smoking history, primary tumor, concurrent diseases or complications.) and treatment conditions (DILD-causing drugs, clinical symptoms, chest CT, DILD treatment drugs, onset cycle, onset time, severity of DILD, DILD course and prognosis.).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The median age of 12 DILD cases was 68%, 66.67% of the patients were male, lung cancer accounted for 58.33% (7\/12). DILD was induced by cytotoxicity drugs, targeted drugs and immune checkpoint inhibitors (ICIs), of which ICIs accounted for 66.67% (8\/12). Scattered patchy, cord-like, grid-like or flocculent shadows were observed on chest CT, mainly under the pleura of lungs. Once DILD occurs, the suspected antineoplastic agents were stopped and glucocorticoid was given, among which 83.33% (10\/12) patients were treated with antibiotics. Finally, 16.67% (2\/12) were cured, 33.33% (4\/12) were improved, 16.67% (2\/12) were not cured and 33.33% (4\/12) were dead.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Antineoplastic agents-induced ILD is mostly found in elderly male lung cancer patients with smoking history. The clinical symptoms of DILD are diverse and lack of specificity. ICIs-ILD has the characteristic of high incidence and poor prognosis compared with other antineoplastic agents. Comprehensive evaluation before medication, regular review, early and adequate glucocorticoid shock therapy after onset can improve the prognosis of DILD patients.<\/jats:p>","DOI":"10.3389\/fphar.2023.1218480","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T13:21:10Z","timestamp":1693228870000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Analysis of 12 cases of antineoplastic agents-induced interstitial lung disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Xiao","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Li","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeng-Xian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","article-title":"Predictive factors for interstitial lung disease, antitumor response, and survival in non- small-cell lung cancer patients treated with gefitinib","volume":"24","author":"Ando","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"B2","volume-title":"CSCO Guidelines Management of immune checkpoint inhibitor-related toxicity","year":"2022"},{"key":"B3","doi-asserted-by":"publisher","first-page":"100404","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur. Respir. J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/diagnostics10040244","article-title":"HRCT Patterns of Drug-Induced Interstitial Lung Diseases: A Review","volume":"10","author":"Distefano","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3779\/j.issn.1009-3419.2021.102.39","article-title":"Osimertinib Re-challenge for EGFR- mutant NSCLC after Osimertinib-induced Interstitial Lung Disease: A Case Report","volume":"24","author":"Gu","year":"2021","journal-title":"Chin J Lung Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1440-1843.2009.01666.x","article-title":"Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy","volume":"15","author":"Isobe","year":"2010","journal-title":"Respirology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00432-022-03932-3","article-title":"Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world","volume":"148","author":"Kaku","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00467-010-1476-3","article-title":"New therapies, new concerns: rituximab-associated lung injury","volume":"25","author":"Lands","year":"2010","journal-title":"Pediatr. Nephrol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1183\/09031936.00080209","article-title":"Rituximab- induced lung disease: A systematic literature review","volume":"35","author":"Liot\u00e9","year":"2010","journal-title":"Eur. Respir. J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1465-9921-13-39","article-title":"Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches","volume":"13","author":"Matsuno","year":"2012","journal-title":"Respir. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2213-0802-2-4","article-title":"Diagnosis and management of interstitial lung disease","volume":"2","author":"Meyer","year":"2014","journal-title":"Translational respiratory medicine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in Patients Treated With Anti-Programmed Death-1\/Programmed Death Ligand 1 Therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B14","volume-title":"Workbook for adverse drug reaction reporting and monitoring","year":"2017"},{"key":"B15","volume-title":"NCCN Guidelines Management of immunotherapy-related toxicities (2Version 1)","author":"National Comprehensive Cancer Network","year":"2023"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00026","article-title":"Drug-Related Pneumonitis in the Era of Precision Cancer Therapy","volume":"1","author":"Nishino","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1038\/sj.bjc.6602061","article-title":"The epidemiology of interstitial lung disease and its association with lung cancer","volume":"91","author":"Raghu","year":"2004","journal-title":"Br. J. Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S2213-2600(18)30172-3","article-title":"Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy","volume":"6","author":"Rashdan","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/s0378-4274(99)00281-7","article-title":"Drug-induced inflammatory responses to the lung","author":"Ryrfeldt","year":"2000","journal-title":"Toxicol. Lett."},{"key":"B20","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/1060028014566446","article-title":"Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer","volume":"49","author":"Sakurada","year":"2015","journal-title":"Ann Pharmacother"},{"key":"B21","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/jcm7100356","article-title":"Drug-Induced Interstitial Lung Disease: A Systematic Review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J Clin Med"},{"key":"B22","first-page":"1186","article-title":"Esophageal carcinoma complicated with albumin-bound paclitaxel-associated interstitial pneumonia: a case report and literature review","volume":"18","author":"Tan","year":"2020","journal-title":"Oncology progresss"},{"key":"B23","first-page":"241","article-title":"FUSCC criteria for the management of targeted drug-induced interstitial lung disease in solid tumors","volume":"31","author":"Zhang","year":"2021","journal-title":"China Oncology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1218480\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T13:21:18Z","timestamp":1693228878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1218480\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":23,"alternative-id":["10.3389\/fphar.2023.1218480"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1218480","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,28]]},"article-number":"1218480"}}